Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches. If you have the appropriate software installed, you can download article citation data to the citation manager ...

After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We already know CAR T, cellular therapy, ...

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...

People with mantle cell lymphoma (MCL) often need to try different treatments to control their cancer. MCL can be hard to treat because it is aggressive and usually not curable. Jaypirca offers a new ...

Treatment with acalabrutinib/BR reduced the risk of disease progression or death by 27% compared with placebo/BR. The Food and Drug Administration (FDA) has granted Priority Review to acalabrutinib ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. Findings showed acalabrutinib with BR reduced ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So I touched on that a minute ago when I ...

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches The following represents disclosure information provided by authors of this manuscript. All relationships are ...